These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20837824)

  • 1. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.
    Geldmacher DS; Fritsch T; McClendon MJ; Landreth G
    Arch Neurol; 2011 Jan; 68(1):45-50. PubMed ID: 20837824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial.
    Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Ibrahim K; Strasser RH; Braun-Dullaeus RC
    Cardiology; 2015; 131(3):165-71. PubMed ID: 25967848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
    Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
    Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
    Miller BW; Willett KC; Desilets AR
    Ann Pharmacother; 2011 Nov; 45(11):1416-24. PubMed ID: 22028424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
    Tolman KG; Freston JW; Kupfer S; Perez A
    Drug Saf; 2009; 32(9):787-800. PubMed ID: 19670918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone for the treatment of Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial.
    Schmitz JM; Green CE; Hasan KM; Vincent J; Suchting R; Weaver MF; Moeller FG; Narayana PA; Cunningham KA; Dineley KT; Lane SD
    Addiction; 2017 Oct; 112(10):1861-1868. PubMed ID: 28498501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
    Sato T; Hanyu H; Hirao K; Kanetaka H; Sakurai H; Iwamoto T
    Neurobiol Aging; 2011 Sep; 32(9):1626-33. PubMed ID: 19923038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
    Watson GS; Cholerton BA; Reger MA; Baker LD; Plymate SR; Asthana S; Fishel MA; Kulstad JJ; Green PS; Cook DG; Kahn SE; Keeling ML; Craft S
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):950-8. PubMed ID: 16286438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
    Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
    Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).
    Shafiq N; Malhotra S; Pandhi P; Gupta M; Kumar B; Sandhu K
    Int J Dermatol; 2005 Apr; 44(4):328-33. PubMed ID: 15811089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.